ArticleScientific reports2025
Unveiling the multitarget mechanism of Liuwei Dihuang decoction in autism spectrum disorder via network pharmacology and molecular docking.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Liuwei Dihuang decoction (LW) is used for paediatric autism spectrum disorders (ASD) treatment, but its mechanism of action is unclear. This study aims to provide clinical evidence for LW in treating ASD in children and investigate its mechanism through network pharmacology, microarray analysis, and molecular docking. A retrospective review of 80 clinical cases of children with ASD and the therapeutic effect of LW was conducted. Drug-disease co-expressed genes were used to construct PPI network maps. The active ingredients of LW were obtained from the TCMSP, CNKI, and PubMed, with screening criteria of OB ≥ 30% and DL ≥ 0.18. Disease targets were sourced from the GeneCards, OMIM, and DisGeNET databases. Core targets were further analyzed using GO and KEGG. Microarray data were employed to analyze the expression levels of the core targets. Molecular docking and dynamics simulations were performed on protein-ligand complexes. MD simulations were performed using GROMACS 2022 for 100 ns, and the stability of the complex was evaluated by analyzing key parameters including RMSD, RMSF, and hydrogen bond occupancy. LW showed promising therapeutic effects on ASD, with efficacy decreasing with age. Quercetin, Tetrahydroalstonine, Diosgenin and Kaempferol were identified as active compounds. PTGS2 and MMP9 were upregulated and identified as key genes in ASD treatment. The binding energies of the key complexes PTGS2-Quercetin, PTGS2-Tetrahydroalstonine, MMP9-Diosgenin, and MMP9-Kaempferol were determined to be - 9.5 kJ/mol, - 9.4 kJ/mol, - 8.1 kJ/mol, and - 7.2 kJ/mol, respectively. Molecular simulations showed favorable binding between key genes and active compounds. This study provides clinical evidence for the treatment of ASD with LW, and predicts its main active ingredients, potential pathways, and core targets, providing a reliable basis for the clinical treatment and drug screening of ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.